ZA200700958B - Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I - Google Patents
Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I Download PDFInfo
- Publication number
- ZA200700958B ZA200700958B ZA200700958A ZA200700958A ZA200700958B ZA 200700958 B ZA200700958 B ZA 200700958B ZA 200700958 A ZA200700958 A ZA 200700958A ZA 200700958 A ZA200700958 A ZA 200700958A ZA 200700958 B ZA200700958 B ZA 200700958B
- Authority
- ZA
- South Africa
- Prior art keywords
- homoestra
- trien
- oxo
- homo
- fluoro
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 19
- 101710088194 Dehydrogenase Proteins 0.000 title description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- -1 alkylaryl radical Chemical class 0.000 claims description 24
- 150000003431 steroids Chemical class 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 claims 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 27
- 230000001419 dependent effect Effects 0.000 abstract description 15
- 239000000262 estrogen Substances 0.000 abstract description 15
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 abstract 1
- 101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 abstract 1
- 101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 229940011871 estrogen Drugs 0.000 description 14
- 229960005309 estradiol Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 229930182833 estradiol Natural products 0.000 description 12
- 239000003826 tablet Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000008177 pharmaceutical agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229960003399 estrone Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 description 3
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229960005471 androstenedione Drugs 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RAJWOBJTTGJROA-UHFFFAOYSA-N (5alpha)-androstane-3,17-dione Natural products C1C(=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 RAJWOBJTTGJROA-UHFFFAOYSA-N 0.000 description 2
- RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 2
- 108010078554 Aromatase Proteins 0.000 description 2
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020005199 Dehydrogenases Proteins 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000005262 Sulfatase Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DJEKMVJLSAUQAO-BBCBXFPWSA-N (8R,9S,13S,14S)-13-methyl-16-methylidene-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol Chemical class C=C1C[C@@H]2[C@](C1O)(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 DJEKMVJLSAUQAO-BBCBXFPWSA-N 0.000 description 1
- BISDOJLVZWYNFW-MVWRLGRASA-N (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-2-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 BISDOJLVZWYNFW-MVWRLGRASA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- ANPHVANSJXDRTP-BSXFFOKHSA-N 16-Ketoestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(C(=O)C4)=O)[C@@H]4[C@@H]3CCC2=C1 ANPHVANSJXDRTP-BSXFFOKHSA-N 0.000 description 1
- 102000004026 17-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108010082514 17-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LGHBWDKMGOIZKH-CBZIJGRNSA-N 3-Deoxyestrone Chemical class C1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LGHBWDKMGOIZKH-CBZIJGRNSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 238000006220 Baeyer-Villiger oxidation reaction Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000027877 Disorders of Sex Development Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 238000006036 Oppenauer oxidation reaction Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 201000005613 Pseudohermaphroditism Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 1
- 102100038021 Steryl-sulfatase Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001337 aliphatic alkines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 150000002167 estrones Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940086546 synarel Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to novel 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula (I) wherein R<SUP>2</SUP> represents a C<SUB>1</SUB>-C<SUB>8</SUB> alkyl, a C<SUB>1</SUB>-C<SUB>8</SUB> alkyloxy group or a halogen atom, R<SUP>13</SUP> represents a hydrogen atom or a methyl group, and R<SUP>17</SUP> represents a hydrogen atom or a fluorine atom. The invention also relates to the pharmaceutically acceptable salts of said compounds, to the production thereof, and to the use of the same as medicaments for the prophylaxis and treatment of oestrogen-dependent diseases that can be influenced by the inhibition of 17ß-hydroxysteroid dehydrogenase type 1.
Description
C3 '§802/0V +58 i .
New 2-Substituted D-Homo-estra-1,3,5(10)-trienes as Inhibitors of 173-Hydroxy
Steroid Dehydrogenase Type 1
This invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes, their production and use as pharmaceutical agents for the treatment of estrogen-dependent diseases that can be influenced by inhibition of the 17B-hydroxy steroid dehydrogenase type 1, as well as pharmaceutical compositions that contain these compounds.
Sex hormones control the proliferation and function of steroid-sensitive normal tissue as well as malignant tissue [E. E. Baulieu, Hormones, A Complex Communi- cation Network. In Hormones, eds. E. E. Baulieu and P. A. Kelly, Herman Publisher
Paris and Chapman and Hall New York, 1990, pp. 147-149; D. D. Thomas, Cancer 53 (1984) 595-601].
Estradiol is the most active female sex hormone, which, in addition to the known effects on the reproductive system, exerts additional functions in bone and lipid metabolism and in the cardiovascular system, as well as regulatory effects in the central nervous system. It is produced primarily in the ovaries in premenopausal women. An additional large portion of the active estrogens is formed in the peripheral tissue from inactive steroid precursors, which are released into the blood in large amounts in the adrenal glands in humans.
After menopause, the estradiol level in the blood drops to about 1/10 of the content of premenopausal women [T. Thorsten, M. Tangen, K. F. Stoa, Eur. J. Cancer
Clin. Oncol. 18 (1982) 333-337; A. A. van Landeghem et al., Cancer Res. 45 (1985) 2900-2906]. Starting from this time, estrogens are mainly available in the peripheral
®
PY 2007400 =3 8 tissue via biosynthesis [F. Labrie, Intracrinology. Mol. Cell. Endocrinol. 78(1991) Cl 13-
C118].
Estrogens are taken up via the blood from tumor tissue and stimulate growth thereof.
The concentration of the intratumoral estradiol remains unchanged at a high level, however, even after menopause, comparable to that in premenopausal women [A.
A. van Landeghem et al., Cancer Res. 45 (1985) 2900-2906]. The high estradiol concentration in the tumor tissue in postmenopausal women is produced by biosynthesis of estrogens in the tumor tissue.
Estradiol (E2) is formed in breast cancer tissue either via the aromatase method or the sulfatase method [Y. J. Abul-Hajj, R. Iverson, D. T. Kiang, Steroids 33 (1979) 205-222; A. Lipton et al., Cancer 59 (1987), 779-782; E. Perel etal., J. Steroid Biochem. 29 (1988) 393-399]. Androstenedione is taken up from the blood by tumor tissue, aromatized to estrone (E1) and then reduced to estradiol (E2) (aromatase method). In the sulfatase method, estrogen sulfate is converted by the steroid sulfatase into E1 and in turn reduced to E2.
The decisive last step of the steroid synthesis is catalyzed by 17f-hydroxy steroid dehydrogenases (17B-HSD), corresponding to the family of 173-hydroxy steroid de- hydrogenases/17-keto steroid reductases. These enzymes convert less active 17-keto steroids into their active 17p-hydroxy steroids and vice versa. Both estrogens and androgens show the highest affinity for the corresponding receptors in the 173-hydroxy form, i.e., the 17p-HSD-enzymes control the biological activity of the sex hormones [H.
Peltoketo et al., J. Mol. Endocrinol. 23 (1999), 1-11; P. Vihko et al., Mol. Cell.
Endocrinol. 171 (2001) 71-76].
Certain extragonadal tissues such as breast and prostate tissue express reductive
® ~ RQY7/00558 17-HSDs and thus convert the precursors that circulate in the blood with low activity in the target tissues into more active forms [F. Labrie et al., Steroids 62 (1997) 148-158; H.
Peltoketo et al., Horm. 55 (1999) 353-398].
Up until now, 11 different 17B-HSDs have been known. They differ in their tissue distribution, the catalytic activity, their substrate specificity, subcellular localization and by the regulation mechanism. For a large number of hydroxy steroid dehydrogenases, it was possible to show their participation in the pathogenesis of diseases of humans, for example for pseudohermaphroditism [17B-HSD 3, W. M.
Geissler et al., Nat. Genet. 7 (1994) 34-39], bifunctional enzyme deficit [17B-HSD 4, E.
G. van Grunsven et al., Proc. Natl. Acad. Sci. USA 95 (1998) 2128-2133], polycystic nephropathy [178-HSD 8, M. M. Maxwell et al, J. Biol. Chem. 270 (1995) 25213- 25219] and Alzheimer’s disease [173-HSD 10, S. D. Yan et al., Nature 389 (1997) 689- 695; X. Y. He et al., J. Biol. Chem. 274 (1999) 15014-15019].
The human placental 17B-hydroxy steroid dehydrogenases type 1 and type 2 belong to the same steroid dehydrogenase-reductase-protein family (SDR). They are distinguished from one another by, i.a., the direction of reaction, which is catalyzed by the enzymes. 17B-HSD 1 primarily controls the reduction of estrone to estradiol [T. Puranen et al., Endocrinology 138 (1997) 3532-3539] with participation by NADPH as a co-factor [J. Z. Jin, S. X. Lin, Biochem. Biophys. Res. Commun. 259 (1999) 489-493].
In cultivated cells, the HSD 1 partially supports the reduction of androstenedione and androstanedione. It could clearly be shown, however, that phenolic substrates are preferred [M. Poutanen et al., Endocrinology 133 (1993) 2639-2644].
In comparison to 17B3-HSD 1, however, the 173-HSD 2 catalyzes the opposite reaction, namely the conversion of estradiol to estrone and of androstenedione and od 4 [ : dihydrotestosterone to androstanedione [L. Wu et al., J. Biol. Chem. 268 (1993) 12964- 12969] and preferably acts in the presence of the non-phosphorylated form of the co- factor NAD [F. Labrie et al., Steroids 62 (1997) 148-158]. 17B-HSD 1 and 2 are expressed in normal mammary gland tissue [G. Soderqvist,
J. Clin. Endocrinol. Metab. 83 (1998) 1190-1193; M. Miettinen, Breast Cancer Res.
Treat. 57 (1999) 175-182].
In contrast to the normal breast tissue, the reductive activity (by 17p-HSD 1) in malignant breast epithelial cells is found to be increased compared to the oxidative activity (by 17B-HSD 2) [M. M. Miettinen et al., Biochem. J. 314 (1996) 839-845; V.
Speirs, J. Steroid Biochem. Mol. Biol. 67 (1998) 267-274]. It was observed that estradiol is accumulated in malignant breast cells, which also points to an activity of 178-HSD 1 [A. Vermeulen et al., Eur. J. Cancer Clin. Oncol. 22 (1986) 515-525]. In addition, it was found that in the presence of 17p-HSD 1, the administration of estrone leads in the same way to a growth of breast cancer cells just like the administration of estradiol by itself. In contrast to this, the administration of estrone by itself without 17p-
HSD 1 does not produce this effect [M. M. Miettinen et al., Int. J. Cancer 68 (1996) 600- 604].
The dominance of 173-HSD 1 in malignant tissue results in increased estrogen- dependent growth and progress of tumors, while the oxidative 173-HSD 2 protect normal breast tissue cells from an excessive estradiol effect [P. Vihko et al. Mol. Cell.
Endocrinol. 171 (2000) 71-76).
In the case of endometriosis, the equilibrium between 173-HSD 1 and 2 plays a role. 17B-HSD 1 is expressed in eutopic tissue, but the hormone-inactivating enzyme 17B-HSD 2 is completely lacking [S. E. Bulun et al. J. Mol. Endocrinol. 25 (2000) 35-
® 5
Also, in the case of prostate cancers, 173-HSD 2 is reduced [J. P. Elo et al,,
Endocrinol. Metab. 88 (2003) 705-712].
Among the previously developed 17B-HSD 1 inhibitors, the irreversible inhibitors are distinguished from the reversible inhibitors. The irreversible inhibitors contain a reactive functional group, which inactivates the latter by forming a covalent bond with an amino acid radical of the enzyme. Known representatives of the above- mentioned group are 16-methylene-estradiols, acetylene-substituted 16-seco-estradiol [R. J. Auchus, D. F. Covey, Biochemistry 25 (1983) 7295-7300; J. L. Thomas et al, J.
Biol. Chem. 258 (1983) 11500-11504; B. Tobias et al., J. Biol. Chem. 257 (1982) 2783- 2786) or else 16a-haloalkyl-estradiols [K. M. Sam et al., Drug Des. Discov. 15 (1997) 157-180; M. R. Tremblay, D. Poirier, J. Steroid Biochem. Mol. Biol. 66 (1998) 179- 191].
The reversible inhibitors include 16,17-pyrazole- or 16,17-isoxazole-estrone derivatives [F. Sweet et al. Biochem. Biophys. Res. Commun. 180 (1991), 1057-1063], estradiol derivatives with a long 7a-undecanamide side chain [C. Labrie et al. Cancer
Res. 52 (1992), 610-615; S. J. Santner, R. J. Santen, J. Steroid Biochem. Mol. Biol. 45 (1993) 383-390] or with a 6B-thiaheptanamide side chain [D. Poirier, P. Dionne, S.
Auger, J. Steroid Biochem. Mol. Biol. 64 (1998), 83-90].
A special case as a 173-HSD I-inhibitor is the 16-oxoestrone: at a neutral pH of 7.2. it includes the reversible inhibitors, and under basic conditions at a pH of 8.5, it includes the irreversible inhibitors [H. Inano, B. Tamaoki, Eur. J. Biochem. 129 (1983) 691-695].
The previously known, both reversible and irreversible inhibitors have only one moderate activity as 173-HSD 1 inhibitors.
The first hybrid inhibitor was recently found by modeling studies [M. Tremblay,
_
D. Poirier et al., FASEB 13 (2002) 1829-1831]. The hybrid inhibitor, in which estradiol is linked to adenosine via a spacer that consists of 8 methylene groups at 16-position, inhibits the 17B-HSD 1 as the best inhibitor to date with an ICs, value of 52 nmol.
Because of the size of this molecule, making this compound bioavailable orally would be difficult. It is not unlikely that the molecule undergoes a cross reaction with other NAD(P)(H)-dependent enzymes.
From the known prior art, 178-HSD 1 is a target for local inhibition of the estradiol biosynthesis. Accompanying treatment with antihormones, which are to prevent the binding of the active steroid to the corresponding receptor, 173-HSD 1 inhibitors can be used to support treatment of estrogen-dependent diseases.
The object of this invention is therefore to provide additional compounds that inhibit the 17p-HSD 1 selectively. These compounds are to be suitable for treating estrogen-dependent diseases as well as hormone-dependent tumor diseases, which can be influenced by inhibition of the 17B-hydroxy steroid dehydrogenase type 1.
Additional subjects of this invention are the production and use of these compounds as pharmaceutical agents for treating estrogen-dependent diseases as well as hormone-dependent tumor diseases, which can be influenced by inhibition of 17f3- hydroxy steroid dehydrogenase type 1.
The object is achieved according to this invention by the provision of new 2-
° substituted D-homo-estra-1,3,5(10)-trienes of general formula I
RA_ 0
RY
So
JOC
M in which
R? means a saturated or unsaturated C,-Cg-alkyl group, an aralkyl or an alkylaryl radical, a C,-Cs-alkyloxy group or a halogen atom,
R" means a hydrogen atom or a methyl group,
RY means a hydrogen atom or a fluorine atom, whereby the dotted lines in the B- and D-ring of the steroid molecule can be additional double bonds, as well as their pharmaceutically acceptable salts.
In addition, this invention comprises the new compounds as pharmaceutical active ingredients, their production, their therapeutic application and pharmaceutical dispensing forms that contain the new substances.
The compounds of general formula (I) according to the invention or their pharmaceutically acceptable salts can be used for the production of a pharmaceutical agent, in particular for treating estrogen-dependent diseases as well as hormone-dependent tumor diseases that can be influenced by inhibition of the 17B-hydroxy steroid dehydrogenase type 1.
It was determined that the low-molecular 2-substituted D-homoestra-1,3,5(10)- trienes according to the invention produce a selective inhibition of the 173-HSD 1- enzyme activity in vitro that is stronger than the previously known 178-HSD 1
® - ® inhibitors.
Unless further specified otherwise, for the purposes of this invention this is an aryl radical that optionally can be substituted by a phenyl, 1- or 2-naphthyl radical, whereby the phenyl radical is preferred. Unless expressly indicated otherwise, aryl also always includes a heteroaryl radical. Examples of a heteroaryl radical are the 2-, 3-, or 4-pyridinyl radical, the 2- or 3-furyl radical, the 2- or 3-thienyl radical, the 2- or 3- pyrrolyl radical, the 2-, 4- or 5-imidazolyl radical, the pyrazinyl radical, the 2, 4- or 5- pyrimidinyl radical or the 3- or 4-pyridazinyl radical.
As substituents for an aryl or heteroaryl radical, for example, a methyl, ethyl, trifluoromethyl, pentafluoroethyl, trifluoromethylthio, methoxy, ethoxy, nitro, cyano, halogen (fluorine, chlorine, bromine, iodine), hydroxy, amino, mono(C.g-alkyl) or di(C,. g-alkyl)amino, whereby both alkyl groups are identical or different, di(aralkyl)amino, whereby both aralkyl groups are identical or different, can be mentioned.
The C,-C,-alkyl groups for RZ can be saturated or unsaturated and can be partially or completely substituted. As representatives of the saturated alkyl radicals, a methyl, ethyl, n-propyl-, iso-propyl-, n-, iso-, or tert.-butyl, n-, iso- or neo-pentyl group, hexyl, heptyl or octyl can be mentioned. Methyl, ethyl and propyl are preferred.
Allyl and vinyl stand as representatives for unsaturated alkyl radicals.
A methoxy, ethoxy, n-propoxy, iso-propoxy, n-, iso-, or tert.-butoxy, n-, iso- or neo-pentoxy group can stand for the C,-Cs-alkoxy radical R%.
In the case of R?, a chlorine, iodine or bromine atom can stand for a halogen.
Preferred according to this invention are compounds of general formula I, in which R%is a C,-Cs-alkoxy, C,-Cs-alkyl or C;-C3-alkenyl or bromine, or chlorine, and
R'is a hydrogen atom.
The compounds that are mentioned below and use thereof are preferred
° -
® according to the invention:
1) 2-Methoxy-17a-0x0-17a-homoestra-1,3,5(10)-trien-3-ol 1 2) 2-Ethoxy-17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-ol 3) 2-Chloro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-0l 2 4) 2-Bromo-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-0l 3 5) 2-lodo-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-0l 4 6) 2-Chloro-17a-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 3a 7) 2-Chloro-17B-Fluoro-17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-0l 3b 8) 2-Bromo-17a-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 9) 2-Bromo-17p-Fluoro-17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-ol 10) 2-(2-Phenylethyl)-17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-0l 6 11) 2-Allyl-17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-ol 7 12) 2-Allyl-17a-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 13) 2-Allyl-17B-Fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 14) 2-Chloro-17a-oxo-17a-homoestra-1,3,5(10),16-tetraen-3-ol 15) 2-Bromo-17a-oxo-17a-homoestra-1,3,5(10),16-tetraen-3-ol 8 16) 2-Allyl-17a-0x0-17a-homoestra-1,3,5(10),16-tetraen-3-ol 17) 2-Propyl-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 18) 2-Methoxy-17a-0xo-17a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol 19) 2-Ethoxy-17a-oxo-17a-homo- 18a-homoestra-1,3,5(10)-trien-3-ol 20) 2-Chloro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol 21) 2-Bromo-17a-0xo0-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol 22) 2-Iodo-17a-ox0-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol 23) 2-Chloro-17a-Fluoro-17a-oxo-17a-homo-18a-homoestra- 1,3,5(10)-trien-3-ol 24) 2-Chloro-17p-Fluoro-17a-ox0-17a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol
® . ® 25) 2-Bromo-17a-Fluoro-17a-0xo-17a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol 26) 2-Bromo-17B-Fluoro-17a-oxo-17a-homo- 18a-homoestra-1,3,5(10)-trien-3-ol 27) 2-Allyl-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-o0l 28) 2-Allyl-17a-Fluoro-17a-0xo-17a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol 29) 2-Allyl-17p-Fluoro-17a-oxo-17a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol 30) 2-Chloro-17a-oxo-17a-homo-18a-homoestra-1,3,5(10),16-tetraen-3-ol 31) 2-Bromo-17a-o0xo-17a-homo-18a-homoestra-1,3,5(10),1 6-tetraen-3-ol 32) 2-Allyl-17a-o0x0-17a-homo-18a-homoestra-1,3,5(10),1 6-tetraen-3-ol 33) 2-Propyl-17a-oxo-17a-homo-18a-homoestra-1,3,5(10)-trien-3-ol
Pharmacological Data
Inhibition of the Activity of Human 17B-Hydroxy Steroid Dehydrogenase Type 1
The test process is well described in the literature [Adamski, J., Sierralta, W. D,,
Jungblut, P. W., Acta Endocrinol (Copenh.) 121(2) (1989), 161-7] and is depicted below.
Human 17pB-hydroxy steroid dehydrogenases (17B-HSDs) are over-expressed in
E. coli bacteria as His-Tag proteins or as GST-fusion proteins. The suspensions of the bacterial pellets in isotonic common salt solution are used for the determination of enzyme activities of the 178-HSDs or for the study of their influence by potential inhibitors (estrogen derivatives).
The measurements are made in double determination and, if necessary, at various concentrations of potential inhibitors (e.g., in determining the ICs values). In addition to the target enzyme 17B-HSDI, other steroid-metabolizing enzymes are included in the test to study cross reactivities of estrogen derivatives. 3H-Labeled substrate, bacterial suspensions, DMSO (in the control batch; final
® 11 ® 1%) or the potential inhibitors (estrone derivatives in DMSO) as well as suitable cofactors (NADP(H) or NAD(H); 5 mg/ml in HO) are added to a defined volume of 100 mmol of sodium phosphate buffer. The incubation of the samples is carried out at 37°C in a water bath while being shaken, such that in the control (without substances to be tested), a conversion of about 30% is achieved.
The separation of radiolabeled substrate and product is then carried out, after extraction with 1 ml of reversed phase-(RP-18)-cartridges, by means of HPLC on an
RP18 column with acetonitrile:water 1:1 (v/v) as a mobile phase. The radioactivity is detected with the aid of a flow-scintillation counter.
The evaluation of the substrate conversion with and without substances to be tested is performed by the integration of the substrate and product peaks. The conversion of the control is normalized to 100% conversion.
® | 12 ®
Tab. 1 Inhibition of the Human 17B-Hydroxy Steroid Dehydrogenase
Structure
ICs [nmol]
RE
BE
BE
BE
BE
Ra
® 13 ®
Dosage
In general, satisfactory results in the treatment of estrogen-dependent diseases as well as hormone-dependent tumor diseases can be expected if the daily doses encompass a range of 5 ug to 50 mg of the compound according to the invention per kg of body weight. In the case of larger mammals, for example humans, a recommended daily dose lies in the range of 10 pg to 30 mg per kg of body weight.
Suitable dosages for the compounds according to the invention are from 0.005 to 50 mg per day per kg of body weight, depending on the age and constitution of the patient, whereby the necessary daily dose can be administered one or more times.
The formulation of the pharmaceutical preparations based on the new compounds is carried out in a way that is known in the art by the active ingredient being processed with the vehicles, fillers, substances that influence decomposition, binding agents, moisturizers, lubricants, absorbents, diluents, flavoring correctives, coloring agents, etc., that are commonly used in galenicals, and converted into the desired form of administration. In this case, reference is made to Remington's Pharmaceutical Science, 15th Ed., Mack Publishing Company, East Pennsylvania (1980).
For oral administration, in particular tablets, coated tablets, capsules, pills, powders, granulates, lozenges, suspensions, emulsions or solutions are suitable.
For parenteral administration, injection and infusion preparations are possible.
For intra-articular injection, correspondingly prepared crystal suspensions can be used.
For intramuscular injection, aqueous and oily injection solutions or suspensions and corresponding depot preparations can be used.
For rectal administration, the new compounds can be used in the form of suppositories, capsules, solutions (e.g., in the form of enemas) and ointments both for
® systemic and for local therapy.
For pulmonary administration of the new compounds, the latter can be used in the form of aerosols and inhalants.
For topical application, formulations in gels, ointments, fatty ointments, creams, pastes, powders, milk and tinctures are possible. The dosage of the compounds of general formula I should be 0.01% -20% in these preparations to achieve an adequate pharmacological action.
This invention comprises the compounds of general formula I as well as use thereof for the production of a pharmaceutical agent, in particular for treating estrogen- dependent diseases, which can be positively influenced by the inhibition of the 17p- hydroxy steroid dehydrogenase.
The compounds of general formula I according to the invention are preferably used for the production of a pharmaceutical agent for treating hormone-dependent tumor diseases of male and female reproductive glands, male and female sex organs including the mammary glands, in particular prostate cancers or breast cancers.
In addition, the compounds according to the invention for the production ofa pharmaceutical agent for treating endometriosis are preferred.
This invention also relates to the pharmaceutical compositions that contain at least one compound according to the invention, optionally in the form ofa pharmaceutically/pharmacologically compatible salt, without or together with pharmaceutically compatible adjuvants and/or vehicles.
These pharmaceutical compositions and pharmaceutical agents can be provided for oral, rectal, vaginal, subcutaneous, percutaneous, intravenous or intramuscular administration. In addition to commonly used vehicles and/or diluents, they contain at least one compound according to the invention.
®
The pharmaceutical agents of the invention are produced with commonly used solid or liquid vehicles or diluents and the commonly used pharmaceutical-technical adjuvants corresponding to the desired type of administration with a suitable dosage in a known way. The preferred preparations consist in a dispensing form that is suitable for oral administration. Such dispensing forms are, for example, tablets, film tablets, coated tablets, capsules, pills, powders, solutions or suspensions or else depot forms.
The pharmaceutical compositions that contain at least one of the compounds according to the invention are preferably administered orally.
Parenteral preparations, such as injection solutions, are also considered. In addition, for example, suppositories and agents for vaginal application can also be mentioned as preparations.
Corresponding tablets can be obtained by, for example, mixing the active ingredient with known adjuvants, for example inert diluents, such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, explosives such as corn starch or alginic acid, binding agents such as starch or gelatin, lubricants such as magnesium stearate or talc and/or agents for achieving a depot effect, such as carboxylpolymethylene, carboxyl methyl cellulose, cellulose acetate phthalate or polyvinyl acetate. The tablets can also consist of several layers.
Coated tablets can accordingly be produced by coating cores, which are produced analogously to the tablets, with agents that are commonly used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium oxide or sugar. In this case, the coated tablet shell can also consist of several layers, whereby the adjuvants that are mentioned above with the tablets can be used.
Solutions or suspensions of the compounds of general formula [ according to the invention can additionally contain taste-improving agents, such as saccharine, cyclamate, or sugar, as well as, e.g., flavoring substances such as vanilla or orange extract. In addition, they can contain suspending adjuvants, such as sodium carboxymethyl cellulose, or preservatives, such as p-hydroxybenzoates.
®
The capsules that contain compounds of general formula I can be produced by, for example, the compound(s) of general formula I being mixed with an inert vehicle such as lactose or sorbitol and being encapsulated in gelatine capsules.
Suitable suppositories can be produced by, for example, mixing with vehicles that are provided for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof.
The compounds according to the invention can be administered for prophylaxis and for therapy of breast cancer or prostate cancer or endometriosis in combination with one or more of the following active ingredients: 1) Antiandrogens, such as cyproterone acetate, flutamide, casodex, etc. 2) Gonadotropin hormone (GnRH) agonists such as synarel, lupron, busrelin 3) Aromatase inhibitors such as anastrozole, formestane, letrozole, exemestane 4) 5a-Reductase inhibitors, such as finasteride 5) Cytostatic agents, such as vinblastine, daunorubicin 6) VEGF-kinase inhibitors 7) Antigestagens, such as onapristones, mifepristones 8) Antiestrogens such as tamoxifen 9) Antisense oligonucleotides 10) EGF Antibodies
Moreover, the compounds of general formula I according to the invention can be used for therapy and prophylaxis of other pathological conditions that are not mentioned above.
® 17 :
The following examples are used for a more detailed explanation of the subject of the invention, without intending that it be limited to these examples.
Starting from the 17-keto derivatives, 17-oxiranes (M. Hiibner, L. Noack, J. prakt. Chem. 1972, 314, 667), and the corresponding 17a-homo derivatives therefrom (M. Hiibner, K. Ponsold, Z. Chem. 1982, 22, 186) can be produced. The above- mentioned reaction steps can be performed before or after functionalization of the 2- position.
The introduction of halogens in 2-position is carried out by means of ortho- thallation as described in the literature for 17-keto derivatives (P. C. Bulman Page et al,
Tetrahedron 1990, 46, 2059).
The functionalization of the C atom 2 of an estra-1,3,5(10)-trien-17-one derivative is preferably carried out by Friedel-Crafts acylation as described in the literature (T. Nambara et al., Chem. Pharm. Bull. 1979, 18, 474). After alteration of the protective group in 3-position, a 2-carboxy-estra-1,3,5(10)-trien-17-one is generated by
Baeyer-Villiger oxidation (M. B. Smith, J. March, March's Advanced Organic
Chemistry, 5" Edition, Wiley Sons 2001, 1417-1418). The ester is saponified and converted with the corresponding alkyl halide under basic conditions into a 2-alkyl ether.
The cleavage of the protective group in 3-position is carried out as described in the literature (T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, Wiley & Sons, 1999, 249-275). This process or others (P. N. Rao, J. W. Cessac, Steroids 2002, 67, 1065) can be used in accordance with the 17a-homo derivatives.
The corresponding 2-alkyl derivatives can be produced from the 2-acyl derivatives by reduction with sodium borohydride, hydrogenation and subsequent
Oppenauer oxidation (C. Djerassi, Org. React. 1951, 6, 207).
_ .
The introduction of the 2-allyl group can be carried out via a Claisen rearrangement as described in the literature (L. Troisi et al., Tetrahedron Lett. 1999, 40, 1771). It can be further functionalized below analogously to the methods that are described by T. Buskas et al. (J. Org. Chem. 2000, 65, 958).
Longer, also unsaturated or functionalized alkyl radicals in 2-position can be obtained via the Sonogashira coupling of more suitable, optionally correspondingly protected alkines and subsequent (partial) hydrogenation.
The 17-fluorination of the 17a-ketone can be performed as described by A. C.
Stalford et al. (Steroids 1997, 62, 750) or else S. Stavber et al. (Synthesis 2002, 2609).
The synthesis of 16,17-dehydro derivatives can also be performed analogously to known processes (see, e.g., P. N. Rao et al,, Steroids 2002, 67, 1079).
Production Process
Example 1 2-Methoxy-17a-0xo0-17a-homoestra-1,3,5(10)-trien-3-o0l 1 3.61 g of 17a-azidomethyl-3,17B-dihydroxy-2-methoxy-estra-1,3,5(1 0)-triene and 7.5 g of sodium iodide were suspended in 250 ml of acetonitrile and slowly mixed at room temperature with 15 ml of trimethyl silyl chloride. After 4 hours, another 4 ml of trimethyl silyl chloride was added, and after another 2.5 hours, it was mixed with saturated sodium thiosulfate solution and water and extracted with dichloromethane (3x). The combined organic phases were washed with aqueous sodium bicarbonate solution, dried and concentrated by evaporation in a rotary evaporator. Flash chromatography (cyclohexane/ethy! acetate = 10:1 — 7:1 — 5:1) yielded 2.12 g (67%)
® _ ® of 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 1 as colorless crystals. 'H-NMR (CDCl3): 8 = 1.13 (s, 3H; 18-CHj), 2.62-2.71 (m, 1H; 17-H), 2.77 (dd, 2H; 6-CH,), 3.86 (s, 3H; 2-OCH3), 5.48 (s, 1H; 3-OH), 6.63, 6.78 (2 5, 2H; 1-H, 4-H).
Example 2 2-Chloro-17a-o0x0-17a-homoestra-1,3,5(10)-trien-3-0l 2 307 mg (851 pmol) of 3-acetoxy-2-chloro-17a-0xo-17a-homoestra-1 ,3,5(10)- triene was dissolved in 24 ml of dichloromethane/methanol (2:1) and mixed with 45 mg of sodium methanolate. After 1.5 hours, it was neutralized with Amberlite IR120 (H+), filtered, and concentrated by evaporation in a rotary evaporator. Flash chromatography (toluene/ethyl acetate = 25:1) yielded 173 mg (64%) of 2-chloro-17a-oxo-17a- homoestra-1,3,5(10)-trien-3-0l 2 as colorless crystals. 'H-NMR (CDCl): & = 1.12 (s, 3H; 18-CHjs), 2.62-2.82 (m, 2H; 17-H, 6-CHb), 5.39 (s, 1H; 3-OH), 6.72, 7.21 (2's, 2H; 1-H, 4-H).
Example 3 2-Bromo-17a-o0x0-17a-homoestra-1,3,5(10)-trien-3-0l 3 3 was produced analogously to the method, described for 17-keto derivatives, by
P. C. Bulman Page et al., Tetrahedron 1990, 46, 2059. 'H-NMR (CDCls): & = 1.12 (s, 3H; 18-CHj3), 2.62-2.82 (m, 2H; 17-H, 6-CH), 5.41 (s, 1H; 3-OH), 6.73, 7.34 (2 s, 2H; 1-H, 4-H).
_ i ®
Example 4 2-lodo-17a-0x0-17a-homoestra-1,3,5(10)-trien-3-o0l 4 4 was produced analogously to the method, described for the 17-keto derivatives, by P. C. Bulman Page et al., Tetrahedron 1990, 46, 2059. "H-NMR (CDCl3): & = 1.12 (s, 3H; 18-CH3), 2.62-2.71 (ddd, J = 6.8, 14.1, 14.1
Hz, 1H; 17-H), 2.77-2.81 (m, 2 H; 6-CH>), 5.29 (s, 1H; 3-OH), 6.71, 7.52 (2 s, 2H; 1-H, 4-H).
Example 5 2-Chloro-17a-fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 3a and 2-Chloro- 17B-fluoro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-0l Sb 60 mg (188 pmol) of 2-chloro-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-o0l 2 was refluxed with about 190 mg of 1-fluoro-4-hydroxy-1,4-diazonia-bicyclo[2,2,2]-octane bis(tetrafluoroborate) on aluminum oxide in 10 ml of methanol for 5 hours, cooled to room temperature, mixed with IN hydrochloric acid and extracted with dichloromethane. The organic phases are dried and concentrated by evaporation in a rotary evaporator. Purification by means of HPLC (Chiracel OJ-H, n-heptane/2- propanol = 6:4) yielded about 10 mg each of 2-chloro-17a-fluoro-17a-oxo-17a- homoestra-1,3,5(10)-trien-3-ol 5a and 2-chloro-17B-fluoro-17a-oxo- 17a-homoestra- 1,3,5(10)-trien-3-ol Sb as colorless solids. 5a: "H-NMR (CDCl): 8 = 1.13 (s, 3H; 18-CH3), 5.32 (ddd, Jur = 48.8, Jun = 7.4, 12.5 Hz, 1H; 17p-H), 6.72, 7.21 (2 5, 2H; 1-H, 4-H) — '"F-NMR (CDCl): 8 = —192.20 (dd, J = 48.9, 12.8 Hz). 5b: 'H-NMR (CDCl3): 8 = 1.21 (d, J = 3.1 Hz, 3H; 18-CHs), 4.86 (ddd, Jur = 49.2, Ju = 3.9, 6.6 Hz, 1H; 170-H), 6.73, 7.20 (2 5, 2H; 1-H, 4-H) — "F-NMR
® . _ (CDCl3): = — 183.02 - — 183.28 (m).
Example 6 2-(2-Phenylethyl)-17a-0xo0-17a-homoestra-1,3,5(10)-trien-3-ol 6 56 mg (123 pmol) of 3-acetoxy-2-iodo-17a-0xo-17a-homoestra-1,3,5(10)-triene was dissolved in 8 ml of triethylamine/THF (3:1), mixed with 3 mg of palladium(iI) acetate, 5 mg of copper(l) iodide, 6.5 mg of triphenylphosphine and 26 pl of phenyl- acetylene, and stirred for 45 minutes at room temperature under argon. Then, it was diluted with ethyl acetate, washed with IN hydrochloric acid, saturated sodium bicarbonate solution and common salt solution, dried, concentrated by evaporation in a rotary evaporator, and purified by flash chromatography (cyclohexane/ethyl acetate 10:1 — 5:1). 42 mg (80%) of 3-acetoxy-2-(2-phenylethinyl)-17a-0x0-17a-homoestra- 1,3,5(10)-triene was obtained as brown-black crystals. 'H-NMR (CDCl3): 8 = 1.12 (s, 3H; 18-CH3), 2.35 (s, 3H, COCH3), 6.82, 7.50 (2 s, 2H; 1-H, 4-H), 7.31-7.48 (m, SH; Ph) — BC-NMR (CDCl): 8 = 16.79, 20.84, 22.87, 25.59, 25.80, 26.22, 29.75, 32.33, 37.08, 38.14, 42.89, 48.17, 50.17, 84.58, 92.92, 114.101, 121.64, 122.91, 128.12, 129.82, 131.24, 137.92, 138.52, 148.90, 168.97, 215.83. 27 mg (63 pmol) of 3-acetoxy-2-(2-phenylethinyl)-1 7a-oxo0-17a-homoestra- 1,3,5(10)-triene was dissolved in 10 ml of ethyl acetate/THF (9:1), mixed with 3 drops of acetic acid and 55 mg of palladium on activated carbon (10%), and hydrogenated for 3 hours. Then, the catalyst was filtered off, concentrated by evaporation in a rotary evaporator, and co-evaporated several times with toluene. The residue was dissolved in 6 ml of dichloromethane, mixed with 20 ml of methanol and 100 mg of sodium methanolate, and stirred for 2 hours. Then, it was neutralized with Amberlite IR120
® . ® (H+), filtered and concentrated by evaporation in a rotary evaporator. Flash chromatography (cyclohexane/ethyl acetate = 5:1) yielded 16 mg (65%) of 2-(2- phenylethyl)-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 6 as colorless needles. 'H-NMR (CDCl3): 8 = 1.13 (s, 3H; 18-CHj3), 2.85-2.89 (m, 4H, PhCH), 4.46 (s, 1H; OH), 6.48, 7.02 (2's, 2H; 1-H, 4-H), 7.19-7.30 (m, 5H; Ph).
Example 7 2-Allyl-17a-0x0-17a-homoestra-1,3,5(10)-trien-3-ol 7 315 mg (1.11 mmol) of 17a-oxo0-17a-homoestra-1,3,5(10)-trien-3-ol was dissolved in 5 mi of absolute DMF, mixed with 1.8 g of cesium carbonate and 1 ml of allyl bromide and heated for 3 hours to 60°C. Then, it was mixed with ethyl acetate and washed with water and common salt solution. The organic phase was separated, dried, and concentrated by evaporation in a rotary evaporator. Flash chromatography (cyclohexane/ethyl acetate = 40:1 — 20:1 — 10:1) yielded 322 mg (89%) of 3-allyloxy- 17a-0x0-17a-homoestra-1,3,5(10)-triene as colorless crystals. 'H-NMR (CDCl): & = 1.12 (d, 3H; 18-CHj3), 2.62-2.71 (m, 1H; 17-H), 2.83-2.86 (m, 2H; 6-H), 4.50 (d, J = 5.0 Hz, 2H; OCH,), 5.26 (dd, J = 1.2, 10.5 Hz, 1H, =CHH), 5.37 (dd, J= 1.2, 17.2 Hz, 1H; =CHH), 5.99-6.07 (m, 1H; CH=CH,), 6.63 (d, /=2.3
Hz, 1H; 4-H), 6.72 (dd, J = 2.3, 8.2 Hz, 1H; 2-H), 7.20 (d, J = 8.6 Hz, 1H; 1-H). 315 mg (971 pmol) of 3-allyloxy-1 7a-oxo-17a-homoestra-1,3,5(10)-triene was dissolved in 25 ml of diethylaniline under argon and refluxed for 8 hours. Then, it was mixed with ethyl acetate and washed with 1N hydrochloric acid and common salt solution. The organic phase was separated, dried, and concentrated by evaporation in a rotary evaporator. Flash chromatography (cyclohexane/ethyl acetate = 9: 1) yielded 312 mg (99%) of a mixture of the two regioisomers as colorless foam. Separation by means
¢ 23 ® of HPLC (Chirapak AD-H, n-heptane/2-propanol = 8:2) yielded 108 mg of 2-allyl-17a- o0x0-17a-homoestra-1,3,5(10)-trien-3-ol 7 as colorless crystals. "H-NMR (CDCls): 8 = 1.12 (d, 3H; 18-CH,), 2.62-2.71 (m, 1H; 17-H), 2.78-2.82 (m, 2H; 6-H), 3.37 (d, J = 6.3 Hz, 2H; OCH,CH=), 4.89 (s, 1H; OH), 5.12-5.18 (m, 2H, =CH,), 5.94-6.05 (m, 1H; CH=CH), 6.54, 7.02 (2's, 2H; 1-H, 4-H).
Example 8 2-Bromo-17a-o0xo0-17a-homoestra-1,3,5(10),16-tetraen-3-ol 8
TH-NMR (CDCl3): & = 1.05 (d, 3H; 18-CHj3), 2.62-2.71 (m, 1H; 17-H), 5.95 (dd,
J=2.5,10.0 Hz, 1H; =CH), 6.87-6.91 (m, 1H, =CH), 6.74, 7.36 (2's, 2H; 1-H, 4-H) —
BC-NMR (CDCl): & = 15.63, 25.64, 25.85, 27.13, 29.28, 32.08, 38.81, 42.34, 44.45, 45.32, 107.42, 115.37, 127.56, 128.61, 133.76, 137.46, 147.25, 149.79, 205.04.
Claims (5)
1. 2-Substituted D-homo-estratrienes of general formula I, RA_ 0 RY “oS BOG 0) in which R? means a saturated or unsaturated C,-Cg-alkyl group, an aralkyl or an alkylaryl radical, a C;-Cg-alkyloxy group or a halogen atom, R'? means a hydrogen atom or a methyl group, R!7 means a hydrogen atom or a fluorine atom, whereby the dotted lines in the B- and D-ring of the steroid molecule can be additional double bonds, as well as their pharmaceutically acceptable salts.
2. 2-Substituted D-homo-estra-1,3,5(10)-trienes according to claim 1, characterized in that R? is a C,-Cs-alkoxy, C;-Cs-alkyl or C,-Cs-alkenyl or bromine or chlorine.
3. 2-Substituted D-homo-estra-1,3,5(10)-trienes according to claim 1, wherein R? is a methoxy radical or ethoxy radical, a methyl, ethyl or propyl radical as well as an allyl radical.
4. 2-Substituted D-homo-estra-1,3,5(10)-trienes according to claim 1, wherein R'? is a hydrogen atom. AMENDED SHEET
¢ 25 :
®
5. 2.Substituted D-homoestra-1,3,5(10)-trienes according to claim 1, namely 1) 2-Methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 1 2) 2-Ethoxy-17a-oxo-17a-homoestra-1,3,5(1 0)-trien-3-ol 3) 2-Chloro-17a-0x0-17a-homoestra-1,3,5(1 0)-trien-3-ol 2 4) 2-Bromo-17a-o0xo0-17a-homoestra-1,3,5(1 0)-trien-3-ol 3 5) 2-lodo-17a-oxo-17a-homoestra-1,3,5(1 0)-trien-3-ol 4 6) 2-Chloro-17a-Fluoro-17a-oxo-17a-homoestra-1,3,5(1 0)-trien-3-ol Sa 7) 2-Chloro-178-Fluoro-17a-oxo-17a-homoestra-1 ,3,5(10)-trien-3-o0l Sb 8) 2-Bromo-17a-Fluoro-17a-oxo-17a-homoestra-1 ,3,5(10)-trien-3-ol 9) 2-Bromo-17f-Fluoro-17a-oxo-17a-homoestra-1 ,3,5(10)-trien-3-ol 10) 2-(2-Phenylethyl)-17a-oxo0-17a-homoestra-1 ,3,5(10)-trien-3-ol 6 11) 2-Allyi-17a-oxo-17a-homoestra-1,3,5(1 0)-trien-3-ol 7 12) 2-Allyl-17a-Fluoro-17a-0xo0-17a-homoestra-1,3,5 (10)-trien-3-ol 13) 2-Allyl-17B-Fluoro-17a-oxo-17a-homoestra-1,3,5( 10)-trien-3-ol 14) 2-Chloro-17a-0x0-17a-homoestra-1 ,3,5(10),16-tetraen-3-ol 15) 2-Bromo-17a-0x0-17a-homoestra-1,3,5(1 0),16-tetraen-3-ol 8 16) 2-Allyl-17a-0x0-17a-homoestra-1,3,5(10),1 6-tetraen-3-ol 17) 2-Propyl-17a-oxo-17a-homoestra-1,3,5(1 0)-trien-3-ol 18) 2-Methoxy-17a-ox0-17a-homo-18a-homoestra-1 ,3,5(10)-trien-3-ol 19) 2-Ethoxy-17a-oxo- 1 7a-homo-18a-homoestra-1,3,5(1 0)-trien-3-ol 20) 2-Chloro-17a-0x0-17a-homo-18a-homoestra-1 ,3,5(10)-trien-3-ol 21) 2-Bromo-17a-ox0-17a-homo-1 8a-homoestra-1,3,5(10)-trien-3-ol 22) 2-Iodo-17a-0xo-17a-homo-18a-homoestra-1 ,3,5(10)-trien-3-ol 23) 2-Chloro-17a-Fluoro-17a-oxo-17a-homo-1 8a-homoestra-1,3,5(10)- trien-3-ol
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004032673A DE102004032673A1 (en) | 2004-07-02 | 2004-07-02 | New 2-substituted D-homo-estra-1,3,5 (10) -trienes as inhibitors of 17ß-hydroxysteroid dehydrogenase type 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200700958B true ZA200700958B (en) | 2008-07-30 |
Family
ID=35106828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200700958A ZA200700958B (en) | 2004-07-02 | 2007-02-01 | Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1763534B1 (en) |
| JP (1) | JP4871274B2 (en) |
| KR (1) | KR20070035059A (en) |
| CN (1) | CN1980949B (en) |
| AT (1) | ATE458744T1 (en) |
| AU (1) | AU2005259329B8 (en) |
| BR (1) | BRPI0511394A (en) |
| CA (1) | CA2571760C (en) |
| CR (1) | CR8854A (en) |
| DE (2) | DE102004032673A1 (en) |
| DK (1) | DK1763534T3 (en) |
| EA (1) | EA011455B1 (en) |
| EC (1) | ECSP077160A (en) |
| ES (1) | ES2340401T3 (en) |
| HK (1) | HK1103745A1 (en) |
| HR (1) | HRP20100230T1 (en) |
| IL (1) | IL180171A0 (en) |
| MX (1) | MX2007000108A (en) |
| NO (1) | NO20070605L (en) |
| NZ (1) | NZ552515A (en) |
| PL (1) | PL1763534T3 (en) |
| PT (1) | PT1763534E (en) |
| UA (1) | UA92324C2 (en) |
| WO (1) | WO2006003012A1 (en) |
| ZA (1) | ZA200700958B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (en) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| DE102007040243A1 (en) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17beta-hydroxysteriod dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| AR096729A1 (en) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | THERAPEUTICALLY ACTIVE DERIVATIVES OF ESTRATIEN-TIAZOL |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| TW201522359A (en) | 2013-06-25 | 2015-06-16 | Forendo Pharma Ltd | Therapeutically active estratrien-thiazole derivatives |
| CN107207562B (en) | 2014-12-23 | 2020-03-06 | 佛恩多制药有限公司 | Prodrugs of 17β-HSD1 Inhibitors |
| CN107207561B (en) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | Prodrugs of 17 β -HSD 1-inhibitors |
| CZ307437B6 (en) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituted estrone derivatives as selective inhibitors of 17β-hydroxysteoid dehydrogenases |
| CN115716860A (en) | 2017-06-08 | 2023-02-28 | 佛恩多制药有限公司 | 15 beta- [ 3-propionylamino ] -substituted estra-1, 3,5 (10) -trien-17-ones and 17-oximes |
| JP7417608B2 (en) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | Estra-1,3,5(10)-triene compounds fused with a pyrazole ring at the 16(17) position as 17-HSD1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005835A (en) * | 1960-09-13 | 1961-10-24 | Searle & Co | D-homo-18-norestra-1, 3, 5(10)-trien-17alpha-ones and intermediates thereto |
| GB1346691A (en) * | 1970-06-12 | 1974-02-13 | Inst Khim Prirodnykh Soedineny | Stereospecific method for preparing estrane compounds of natural configuration |
| JPH06279488A (en) * | 1993-03-29 | 1994-10-04 | Kuraray Co Ltd | New steroid derivative and osteoporosis treatment agent |
| CA2323089A1 (en) * | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| DE10151365A1 (en) * | 2001-10-17 | 2003-04-30 | Schering Ag | New 17-chloro-D-homosteroids, useful as estrogen receptor ligands for female or male contraception or treating benign or malignant proliferative diseases of the ovary |
| WO2002068548A1 (en) * | 2001-02-27 | 2002-09-06 | Schering Ag | Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| WO2003017973A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method |
| DE10307103A1 (en) * | 2003-02-19 | 2004-09-09 | Schering Ag | Anti-tumor effective 2-substituted D-homostra-1,3,5 (10) -trien-3-yl sulfamate |
| DE102004032674A1 (en) * | 2004-07-02 | 2006-01-26 | Schering Ag | New 2-substituted Estra-1,3,5 (10) -triene-17-ones as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 |
-
2004
- 2004-07-02 DE DE102004032673A patent/DE102004032673A1/en not_active Ceased
-
2005
- 2005-04-07 UA UAA200701040A patent/UA92324C2/en unknown
- 2005-07-04 CN CN2005800225714A patent/CN1980949B/en not_active Expired - Fee Related
- 2005-07-04 EP EP05768705A patent/EP1763534B1/en active Active
- 2005-07-04 KR KR1020077002617A patent/KR20070035059A/en not_active Ceased
- 2005-07-04 DK DK05768705.5T patent/DK1763534T3/en active
- 2005-07-04 AT AT05768705T patent/ATE458744T1/en active
- 2005-07-04 WO PCT/EP2005/007314 patent/WO2006003012A1/en active Application Filing
- 2005-07-04 JP JP2007518557A patent/JP4871274B2/en not_active Expired - Fee Related
- 2005-07-04 DE DE502005009091T patent/DE502005009091D1/en active Active
- 2005-07-04 BR BRPI0511394-6A patent/BRPI0511394A/en not_active IP Right Cessation
- 2005-07-04 ES ES05768705T patent/ES2340401T3/en active Active
- 2005-07-04 PT PT05768705T patent/PT1763534E/en unknown
- 2005-07-04 MX MX2007000108A patent/MX2007000108A/en active IP Right Grant
- 2005-07-04 CA CA2571760A patent/CA2571760C/en not_active Expired - Fee Related
- 2005-07-04 NZ NZ552515A patent/NZ552515A/en not_active IP Right Cessation
- 2005-07-04 AU AU2005259329A patent/AU2005259329B8/en not_active Expired - Fee Related
- 2005-07-04 PL PL05768705T patent/PL1763534T3/en unknown
- 2005-07-04 EA EA200700103A patent/EA011455B1/en not_active IP Right Cessation
-
2006
- 2006-12-19 IL IL180171A patent/IL180171A0/en unknown
-
2007
- 2007-01-10 EC EC2007007160A patent/ECSP077160A/en unknown
- 2007-01-11 CR CR8854A patent/CR8854A/en not_active Application Discontinuation
- 2007-02-01 ZA ZA200700958A patent/ZA200700958B/en unknown
- 2007-02-01 NO NO20070605A patent/NO20070605L/en not_active Application Discontinuation
- 2007-11-08 HK HK07112172.8A patent/HK1103745A1/en unknown
-
2010
- 2010-04-20 HR HR20100230T patent/HRP20100230T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1980949B (en) | 2010-05-05 |
| DK1763534T3 (en) | 2010-05-17 |
| DE502005009091D1 (en) | 2010-04-08 |
| UA92324C2 (en) | 2010-10-25 |
| EA200700103A1 (en) | 2007-08-31 |
| CR8854A (en) | 2007-08-28 |
| ATE458744T1 (en) | 2010-03-15 |
| AU2005259329B8 (en) | 2011-11-24 |
| DE102004032673A1 (en) | 2006-01-26 |
| EP1763534B1 (en) | 2010-02-24 |
| AU2005259329A1 (en) | 2006-01-12 |
| MX2007000108A (en) | 2007-03-09 |
| EA011455B1 (en) | 2009-04-28 |
| JP4871274B2 (en) | 2012-02-08 |
| WO2006003012A1 (en) | 2006-01-12 |
| BRPI0511394A (en) | 2007-12-04 |
| HK1103745A1 (en) | 2007-12-28 |
| CA2571760A1 (en) | 2006-01-12 |
| CA2571760C (en) | 2011-11-22 |
| IL180171A0 (en) | 2007-06-03 |
| AU2005259329B2 (en) | 2011-11-10 |
| CN1980949A (en) | 2007-06-13 |
| PT1763534E (en) | 2010-04-27 |
| EP1763534A1 (en) | 2007-03-21 |
| JP2008504337A (en) | 2008-02-14 |
| KR20070035059A (en) | 2007-03-29 |
| HRP20100230T1 (en) | 2010-06-30 |
| ECSP077160A (en) | 2007-02-28 |
| ES2340401T3 (en) | 2010-06-02 |
| PL1763534T3 (en) | 2010-07-30 |
| NO20070605L (en) | 2007-02-01 |
| NZ552515A (en) | 2010-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200700958B (en) | Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I | |
| US5861388A (en) | Steroid inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use | |
| EP2499151A2 (en) | Mammalian metabolites of steroids | |
| US7732493B2 (en) | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | |
| JP2008504338A (en) | Novel 2-substituted estra-1,3,5 (10) -trien-17-ones as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 | |
| US7419972B2 (en) | 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | |
| JP2566574B2 (en) | Steroids useful as anti-cancer and anti-obesity agents | |
| CA2794565C (en) | Substituted androst-4-ene diones | |
| US20210308144A1 (en) | Synthesis of New Potent Aromatase Inhibitors Through Biocatalysis of Anti-Cancer Drugs, Atamestane, Drostanolone Enanthate, and Exemestane | |
| TW201103547A (en) | 17β-alkyl-17α-oxy-oestratrienes | |
| EP3464314A1 (en) | 15b-substituted estrone derivatives as selective inhibitors of 17b-hydroxysteoid-dehydrogenases, method of preparation and use thereof |